BioCentury | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

...Takeda will present data showing two candidates targeting post-translational modifications--neddylation inhibitor pevonedistat and sumoylation inhibitor TAK-981--each...
...vivo cultures of T cells from chronic lymphocytic leukemia (CLL) patients. The company also reports TAK-981...
...myelogenous leukemia and chronic myelogenous leukemia (CML), and in Phase II testing for solid tumors. TAK-981...
Items per page:
1 - 1 of 1